ARTICLE | Company News
Immunocore, Lilly partner for melanoma combos
June 30, 2015 2:16 AM UTC
Immunocore Ltd. (Abingdon, U.K.) partnered with Eli Lilly and Co. (NYSE:LLY) to study combination regimens including Immunocore's IMCgp100 and Lilly's galunisertib ( LY2157299) and merestinib ( LY2801653) to treat melanoma.
The companies will conduct a Phase Ib/II trial of IMCgp100 plus galunisertib to treat metastatic cutaneous melanoma, and a Phase Ib/II trial of IMCgp100 plus merestinib to treat metastatic uveal melanoma. Both trials are expected to begin in 2016. Immunocore and Lilly declined to disclose financial terms of the deal. ...